How to buy Cardiff Oncology stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cardiff Oncology stock

Own Cardiff Oncology stock in just a few minutes.

Cardiff Oncology, Inc is a biotechnology business based in the US. Cardiff Oncology shares (CRDF) are listed on the NASDAQ and all prices are listed in US Dollars. Cardiff Oncology employs 11 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Cardiff Oncology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CRDF – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cardiff Oncology share price

Use our graph to track the performance of CRDF stocks over time.

Cardiff Oncology shares at a glance

Information last updated 2021-04-15.
52-week range$0.85 - $25.50
50-day moving average $9.98
200-day moving average $14.53
Wall St. target price$26.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.73

Buy Cardiff Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cardiff Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cardiff Oncology financials

Revenue TTM $365,993
Gross profit TTM $-10,869,403
Return on assets TTM -15.89%
Return on equity TTM -28.5%
Profit margin 0%
Book value N/A
Market capitalisation $326.1 million

TTM: trailing 12 months

Shorting Cardiff Oncology shares

There are currently 2.6 million Cardiff Oncology shares held short by investors – that's known as Cardiff Oncology's "short interest". This figure is 51% down from 5.4 million last month.

There are a few different ways that this level of interest in shorting Cardiff Oncology shares can be evaluated.

Cardiff Oncology's "short interest ratio" (SIR)

Cardiff Oncology's "short interest ratio" (SIR) is the quantity of Cardiff Oncology shares currently shorted divided by the average quantity of Cardiff Oncology shares traded daily (recently around 1.0 million). Cardiff Oncology's SIR currently stands at 2.61. In other words for every 100,000 Cardiff Oncology shares traded daily on the market, roughly 2610 shares are currently held short.

However Cardiff Oncology's short interest can also be evaluated against the total number of Cardiff Oncology shares, or, against the total number of tradable Cardiff Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cardiff Oncology's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Cardiff Oncology shares in existence, roughly 70 shares are currently held short) or 0.0715% of the tradable shares (for every 100,000 tradable Cardiff Oncology shares, roughly 72 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cardiff Oncology.

Find out more about how you can short Cardiff Oncology stock.

Cardiff Oncology share dividends

We're not expecting Cardiff Oncology to pay a dividend over the next 12 months.

Have Cardiff Oncology's shares ever split?

Cardiff Oncology's shares were split on a 1:6 basis on 19 February 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiff Oncology shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cardiff Oncology shares which in turn could have impacted Cardiff Oncology's share price.

Cardiff Oncology share price volatility

Over the last 12 months, Cardiff Oncology's shares have ranged in value from as little as $0.85 up to $25.5. A popular way to gauge a stock's volatility is its "beta".

CRDF.US volatility(beta: 1.83)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiff Oncology's is 1.8318. This would suggest that Cardiff Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cardiff Oncology overview

Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site